Novartis Ag (NVS) Gross Margin (2009 - 2026)

Novartis Ag has disclosed Gross Margin across 18 years of filings, most recently posting 78.02% for Q2 2026.

• In Q2 2026, Gross Margin fell 391.0% year-over-year to 78.02%; the TTM figure through Jun 2026 stood at 78.63% (up 33.0% YoY), while the FY2025 annual figure was 78.81%, up 151.0% from the prior year.
• Gross Margin came in at 78.02% for Q2 2026 at Novartis Ag, up from 76.76% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 81.93% in Q2 2025 to a low of 71.49% in Q1 2022.
• Average Gross Margin over 5 years is 76.47%, with a median of 76.52% recorded in 2024.
• Year-over-year, Gross Margin soared 464 bps in 2022 and plunged 391 bps in 2026.
• Over 5 years, Gross Margin stood at 75.73% in 2022, then slipped by 1 bps to 74.77% in 2023, then advanced by 3 bps to 77.12% in 2024, then advanced by 4 bps to 80.28% in 2025, then retreated by 3 bps to 78.02% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 78.02% in Q2 2026, 76.76% in Q1 2026, and 80.28% in Q4 2025.